Dominic Borie
Chief Tech/Sci/R&D Officer at KYVERNA THERAPEUTICS, INC.
Net worth: 6 M $ as of 2024-05-30
Dominic Borie active positions
| Companies | Position | Start | End |
|---|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-10-12 | - |
| Director/Board Member | 2019-12-31 | 2022-10-12 | |
| Chief Executive Officer | 2019-12-31 | 2022-10-12 | |
| President | 2019-12-31 | 2022-10-12 |
Career history of Dominic Borie
Former positions of Dominic Borie
| Companies | Position | Start | End |
|---|---|---|---|
| Stanford University | Corporate Officer/Principal | - | - |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | - | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
| ALLOGENE THERAPEUTICS, INC. | Director/Board Member | - | - |
Training of Dominic Borie
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Statistics
International
| United States | 8 |
| Ireland | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Dominic Borie
- Experience
